What is pjp pneumonia

Overview

Pneumocystis Jirovecii Pneumonia, abbreviated as PJP, is a serious and potentially life-threatening fungal infection of the lungs. It is caused by the opportunistic pathogen Pneumocystis jirovecii. The infection was historically called Pneumocystis Carinii Pneumonia (PCP) until the organism was reclassified in 1994. PJP is one of the most common opportunistic infections associated with HIV/AIDS and other conditions that severely compromise the immune system.

Causes and Risk Factors

PJP is caused by inhalation of spores from the fungus Pneumocystis jirovecii, which exists in the environment. This organism typically does not cause disease in healthy individuals with normal immune function. People at highest risk include those with CD4 T-cell counts below 200 cells (in HIV-positive individuals), organ transplant recipients, people on long-term corticosteroid therapy, and those with other conditions causing severe immunosuppression. Before effective HIV treatment became widely available, PJP was a defining illness of AIDS and a marker of severe immune dysfunction.

Symptoms and Clinical Presentation

Symptoms of PJP typically include progressive shortness of breath, fever, cough, and chest pain, often developing gradually over days to weeks. Unlike bacterial pneumonia which often comes on suddenly, PJP develops insidiously with worsening symptoms. The infection primarily affects the lungs, causing inflammation and impaired oxygen exchange. Patients may experience fatigue and malaise. Diagnosis involves clinical presentation, chest imaging showing characteristic bilateral interstitial infiltrates, and confirmation through identification of the organism in respiratory specimens.

Diagnosis and Laboratory Findings

Diagnosis of PJP combines clinical suspicion with diagnostic testing. Chest X-rays typically show bilateral interstitial infiltrates. Elevated serum lactate dehydrogenase (LDH) is a characteristic laboratory finding that supports diagnosis. Definitive diagnosis requires identification of Pneumocystis organisms through induced sputum samples, bronchoalveolar lavage, or lung biopsy. Polymerase chain reaction (PCR) testing has become increasingly available for rapid diagnosis. Early diagnosis is crucial for initiating timely treatment.

Treatment and Management

PJP is treated with antimicrobial agents, most commonly trimethoprim-sulfamethoxazole (TMP-SMX) for 21 days. Alternative medications are available for those with allergies or intolerance, including pentamidine, atovaquone with dapsone, or clindamycin with primaquine. Prophylactic medication is recommended for all at-risk individuals with CD4 counts below 200 cells to prevent initial infection. With modern antiretroviral therapy, the incidence of PJP has significantly declined among HIV-positive patients in resource-rich settings.